Earnings/Sales releases The Q1 26 Ebitda was materially ahead of expectations, though sales were in line with consensus. Faes is off to a strong start in 2026, thanks to healthy demand for its key...
Faes Farma: Enviable beginning to 2026
Earnings/Sales releases The Q1 26 Ebitda was materially ahead of expectations, though sales were in line with consensus. Faes is off to a strong start in 2026, thanks to healthy demand for its key...